In contrast to CD4+ helper T cells, which mainly participate in anti-tumor immunity and prevent tumor progression, CD4+ regulatory T (TREG) cells, characterized by the expression of lineage-specific transcription factor FOXP3, are the immunosuppressive T cells correlated with tumor progression and poor clinical outcomes. This evidence concerns the gene CD4 and neoplasm.